7a458b19-1b7c-422c-b900-cd77e5009421
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 72.6680355920602
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.470
- MYC_TARGETS_V1+0.460
- OXIDATIVE_PHOSPHORYLATION+0.450
- MTORC1_SIGNALING+0.410
- PANCREAS_BETA_CELLS+0.380
- CHOLESTEROL_HOMEOSTASIS+0.370
- FATTY_ACID_METABOLISM+0.370
- DNA_REPAIR+0.350
- INTERFERON_ALPHA_RESPONSE+0.350
- P53_PATHWAY+0.350
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- TNFA_SIGNALING_VIA_NFKB-0.290
- UV_RESPONSE_DN-0.290
- MITOTIC_SPINDLE-0.230
- NOTCH_SIGNALING-0.230
- KRAS_SIGNALING_UP-0.190
- IL6_JAK_STAT3_SIGNALING-0.180
- MYOGENESIS-0.140
- TGF_BETA_SIGNALING-0.120
- ANGIOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5JE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.808 |
| 2 | SRR25043614 | — | — | 0.808 |
| 3 | MBCProject_0170_T1_RNA | — | C | 0.793 |
| 4 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.786 |
| 5 | BS_JZRM1S3T | Med | Medulloblastoma | 0.782 |
| 6 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.782 |
| 7 | SRR11296765 | — | — | 0.782 |
| 8 | 1a68a242-045b-4566-afd7-192df87b02d3 | — | — | 0.779 |
| 9 | TCGA-A8-A09E-01A-11R-A00Z-07 | — | B | 0.773 |
| 10 | DEACC29A-6DEF-4728-AFEB-15D7BDA850CA | — | — | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |